HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

Autor McDermott, Martina S. J., Conlon, Neil, Browne, Brigid C., Szabo, Adam, Synnott, Naoise C., O’Brien, Neil A., Duffy, Michael J., Crown, John, O’Donovan, Norma
Vydáno v Cancers (Basel) (2019)

Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation

Autor Abreu, Maria Teresa Herrera, Hughes, William E., Mele, Katarina, Lyons, Ruth J., Rickwood, Danny, Browne, Brigid C., Bennett, Haley L., Vallotton, Pascal, Brummer, Tilman, Daly, Roger J.
Vydáno 2011

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Autor McDermott, Martina SJ, Browne, Brigid C, Conlon, Neil T, O’Brien, Neil A, Slamon, Dennis J, Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O’Donovan, Norma
Vydáno v Mol Cancer (2014)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

Autor Eustace, Alex J, Conlon, Neil T, McDermott, Martina S J, Browne, Brigid C, O’Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O’Shaughnessy, Joyce, Gallagher, Clair, O’Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O’Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O’Donovan, Norma, Crown, John
Vydáno v BMC Cancer (2018)